Targeting the cancer kinome through polypharmacology

Nature Reviews Cancer

Volumn 10, Issue 2, 2010, Pages 130-137

  Knight, Zachary A ^a   Lin, Henry ^b   Shokat, Kevan M ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BEVACIZUMAB; CETUXIMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FLAVOPIRIDOL; GEFITINIB; IMATINIB; IRINOTECAN; LAPATINIB; NILOTINIB; PANITUMUMAB; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN RECEPTOR 2;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; DRUG EFFICACY; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CANCER; LUNG CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RNA, SMALL INTERFERING; TECHNOLOGY, PHARMACEUTICAL;

EID: 75149130051     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2787     Document Type: Review

References (97)

1. Akritopoulou-Zanze, I. & Hajduk, P. J. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. Drug Discov. Today 14, 291-297 (2009).
2. Parsons, D. W. et al. Colorectal cancer: mutations in a signalling pathway. Nature 436, 792 (2005).
3. Wood, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113 (2007).
4. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006).
5. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
6. Heinrich, M. C. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342-4349 (2003).
7. Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006).
8. Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456 (2008).
9. Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
10. Yang, J. C. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003).
11. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
12. Shepherd, F. A. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005).
13. Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006). (Pubitemid 44917502)
14. Geyer, C. E. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743 (2006).
15. Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
16. Jonker, D. J. et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357, 2040-2048 (2007).
17. Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966 (2007).
18. Ciardiello, F. & Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160-1174 (2008).
19. Hudis, C. A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51 (2007).
20. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl J. Med. 359, 1757-1765 (2008).
21. Pao, W. et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, 17 (2005).
22. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001).
23. Tamborini, E. et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127, 294-299 (2004).
24. Cools, J. et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201-1214 (2003).
25. Chen, L. L. et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 64, 5913-5919 (2004).
26. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, 73 (2005).
27. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007).
28. Sergina, N. V. et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437-441 (2007).
29. Stommel, J. M. et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287-290 (2007).
30. Mellinghoff, I. K. et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024 (2005).
31. Apsel, B. et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nature Chem. Biol. 4, 691-699 (2008).
32. Sawyers, C. L. Cancer: mixing cocktails. Nature 449, 993-996 (2007).
33. Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531-2541 (2006).
34. Kantarjian, H. et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542-2551 (2006). (Pubitemid 43882350)
35. Shah, N. P. et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 11 7, 2562-2569 (2007).
36. O'Hare, T. et al. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc. Natl Acad. Sci. USA 105, 5507-5512 (2008).
37. Gontarewicz, A. et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111, 4355-4364 (2008).
38. Carter, T. A. et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl Acad. Sci. USA 102, 11011-11016 (2005).
39. O'Hare, T. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401-412 (2009).
40. Giles, F. J. et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109, 500-502 (2007).
41. Weinstein, I. B. et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin. Cancer Res. 3, 2696-2702 (1997).
42. McDermott, U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl Acad. Sci. USA 104, 19936-19941 (2007).
43. Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
44. Shah, N. P. et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14, 485-493 (2008).
45. Fan, Q. W. et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341-349 (2006).
46. Haigis, K. M. et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nature Genet. 40, 600-608 (2008).
47. Fan, Q. W. et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 67, 7960-7965 (2007).
48. Eichhorn, P. J. et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/ phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 68, 9221-9230 (2008).
49. Junttila, T. T. et al. Ligand-independent HER2/HER3/ PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15, 429-440 (2009).
50. Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. Nature Chem. Biol. 4, 682-690 (2008).
51. Repasky, G. A., Chenette, E. J. & Der, C. J. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol. 14, 639-647 (2004).
52. Rodriguez-Viciana, P. et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370, 527-532 (1994).
53. Gupta, S. et al. Binding of ras to phosphoinositide 3-kinase p110α is required for ras-driven tumorigenesis in mice. Cell 129, 957-968 (2007).
54. Wee, S. et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 69, 4286-4293 (2009).
55. Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Med. 14, 1351-1356 (2008).
56. Normanno, N. et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. 13, 65-72 (2002).
57. Moulder, S. L. et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 61, 8887-8895 (2001).
58. Bukowski, R. M. et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol. 25, 4536-4541 (2007).
59. Tonra, J. R. et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res. 12, 2197-2207 (2006).
60. Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563-572 (2009).
61. Arteaga, C. L. et al. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin. Cancer Res. 14, 6277-6283 (2008).
62. Warburton, C. et al. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin. Cancer Res. 10, 2512-2524 (2004).
63. Normanno, N., Campiglio, M., Perrone, F., De Luca, A. & Menard, S. Is the gefitinib plus trastuzumab combination feasible in breast cancer patients? Ann. Oncol. 16, 1709 (2005).
64. Motwani, M. et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin. Cancer Res. 7, 4209-4219 (2001).
65. Shah, M. A. et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin. Cancer Res. 11, 3836-3845 (2005).
66. Torrance, C. J., Agrawal, V., Vogelstein, B. & Kinzler, K. W. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nature Biotechnol. 19, 940-945 (2001).
67. Manning, B. D. Challenges and opportunities in defining the essential cancer kinome. Sci. Signal 2, 15 (2009).
68. Goldman, B. For investigational targeted drugs, combination trials pose challenges. J. Natl Cancer Inst. 95, 1744-1746 (2003).
69. Chen, H. Optimising strategies for clinical development of combinations of targeted agents. Eur. J. Cancer Suppl. 5, 46-52 (2007).
70. Winslow, R. AstraZeneca, Merck to Test Cancer Drugs in 'Cocktail'. The Wall Street Journal [online], http://online.wsj.com/article/ SB124380640803770139.html (2009).
71. Barry, D. W. & Distlerath, L. M. History and accomplishments of the inter-company collaboration for AIDS drug development. Drug Inf. J. 34, 741-752 (2000).
72. Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848 (2009).
73. Scholl, C. et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834 (2009).
74. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009).
75. Meylan, E. et al. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature 462, 104-107 (2009).
76. Baldwin, A. et al. Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells. Proc. Natl Acad. Sci. USA 105, 16478-16483 (2008).
77. Grueneberg, D. A. et al. Kinase requirements in human cells: I. Comparing kinase requirements across various cell types. Proc. Natl Acad. Sci. USA 10 5, 16472-16477 (2008).
78. Morgan-Lappe, S. et al. RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. Oncogene 25, 1340-1348 (2006).
79. Luo, Y. et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol. Cancer Ther. 4, 977-986 (2005).
80. Knight, Z. A. & Shokat, K. M. Chemical genetics: where genetics and pharmacology meet. Cell 128, 425-430 (2007).
81. Lyons, J. F., Wilhelm, S., Hibner, B. & Bollag, G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 8, 219-225 (2001).
82. Hauschild, A. et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 27, 2823-2830 (2009).
83. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
84. Strumberg, D. et al. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int. J. Clin. Pharmacol. Ther. 40, 580-581 (2002).
85. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. & Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287-1295 (2003).
86. Gleich, G. J., Leiferman, K. M., Pardanani, A., Tefferi, A. & Butterfield, J. H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359, 1577-1578 (2002).
87. Burdine, L. & Kodadek, T. Target identification in chemical genetics: the (often) missing link. Chem. Biol. 11, 593-597 (2004).
88. Knight, Z. A. & Shokat, K. M. Features of selective kinase inhibitors. Chem. Biol. 12, 621-637 (2005).
89. Davies, S. P., Reddy, H., Caivano, M. & Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105 (2000).
90. Bain, J. et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297-315 (2007).
91. Bamborough, P., Drewry, D., Harper, G., Smith, G. K. & Schneider, K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J. Med. Chem. 51, 7898-7914 (2008).
92. Hopkins, A. L., Mason, J. S. & Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16, 127-136 (2006).
93. Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnol. 26, 127-132 (2008).
94. Samuels, Y. et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561-573 (2005).
95. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
96. Fabian, M. A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnol. 23, 329-336 (2005).
97. Fedorov, O. et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl Acad. Sci. USA 104, 20523-20528 (2007).